Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche/Genentech in race for CAR-T therapy in solid tumors

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Sep 27, 2022 11:29am

502 Views

Post# 34989459

Roche/Genentech in race for CAR-T therapy in solid tumors

September 27, 2022 - "In the race to create a CAR-T therapy that can treat solid tumors, Genentech has decided it needs all the help it can get. The Roche unit has fronted $70 million to use Arsenal Biosciences’ armory of screening and T-cell engineering tools to find a truly successful target."

"The first generation of CAR-Ts scored successes against hematological malignancies, and Big Pharma already has its sights set on the next generation including "off-the-shelf" variations. Yet an approval to treat solid tumors has remained tantalizing out of reach, with Novartis and AstraZeneca among the big players that have outlined their solid tumor CAR-T ambitions..."

"Roche has been late to the CAR-T game, only joining the action last year with a $3 billion Adaptimmune Therapeutics deal for off-the-shelf T-cell therapies followed by a $110 million agreement with Poseida Therapeutics for a clutch of CAR-Ts last month."

https://www.fiercebiotech.com/biotech/genentech-pays-70m-access-arsenals-armoury-t-cell-tools-quest-solid-tumor-car-t

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta